2300002D11Rik Inhibitors
Chemical inhibitors of 2300002D11Rik can modulate the activity of this protein by targeting various signaling pathways in which it is involved. LY294002 and Wortmannin are two such inhibitors that directly target PI3K, an upstream kinase in the PI3K/Akt signaling pathway. By inhibiting PI3K, these chemicals prevent the phosphorylation and subsequent activation of downstream targets, including 2300002D11Rik. Rapamycin takes a different approach, inhibiting mTOR, a component of the mTOR signaling pathway, which is also connected to the cellular processes that involve 2300002D11Rik. Inhibition of mTOR by Rapamycin leads to reduced activity of proteins that operate downstream in the mTOR pathway, which includes 2300002D11Rik.
The MAPK/ERK and p38 MAPK pathways are another set of targets for the modulation of 2300002D11Rik activity. PD98059 and U0126 are selective inhibitors that block MEK1/2, thereby disrupting the activation of ERK in the MAPK/ERK pathway. Without active ERK, the signaling cascade that might normally involve 2300002D11Rik is interrupted. Similarly, SB203580 specifically inhibits p38 MAPK, and by doing so, it affects the p38 MAPK signaling pathway and the function of any proteins modulated by this pathway, including 2300002D11Rik. SP600125, which inhibits JNK, and PP2, an inhibitor of Src family kinases, both prevent the activation of their respective kinase targets, leading to a decrease in the phosphorylation-dependent regulation of proteins like 2300002D11Rik. Dasatinib, with its broad-spectrum kinase inhibition, can suppress the activity of Src family kinases, and by extension, it can inhibit the function of 2300002D11Rik. Erlotinib inhibits EGFR tyrosine kinase, potentially impacting the EGFR signaling pathway and its associated proteins, including 2300002D11Rik. Lastly, Sorafenib and Triciribine target the RAF/MEK/ERK and Akt pathways, respectively, and by inhibiting these pathways, they can suppress the function of proteins such as 2300002D11Rik that are regulated via these pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is involved in the Akt signaling pathway. 2300002D11Rik, as part of this pathway, is inhibited as LY294002 prevents PI3K from phosphorylating downstream targets that would be necessary for 2300002D11Rik's function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that irreversibly inhibits the kinase, thereby inhibiting the PI3K/Akt pathway. This inhibition can prevent the activation of downstream proteins such as 2300002D11Rik by ensuring that the necessary phosphorylation for its activity does not occur. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a kinase that is part of the mTOR signaling pathway. Since mTOR is involved in cell growth and proliferation, its inhibition by Rapamycin would result in the downregulation of cellular processes that require the function of 2300002D11Rik, thereby inhibiting the protein's activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is upstream of ERK in the MAPK/ERK pathway. By inhibiting MEK, PD98059 disrupts the phosphorylation of ERK and its subsequent signaling, which could be crucial for the function of 2300002D11Rik in the pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2, leading to the inhibition of the MAPK/ERK pathway. This blockade prevents the activation of downstream elements that would otherwise be involved in the functional regulation of 2300002D11Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK affects the p38 MAPK signaling pathway, which may be necessary for the regulation and function of 2300002D11Rik. Without the proper signaling through p38, 2300002D11Rik is inhibited. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which affects the JNK signaling pathway. By inhibiting JNK, SP600125 prevents the phosphorylation and activation of proteins that are regulated by this pathway, including potentially 2300002D11Rik, thereby inhibiting its function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases can phosphorylate a variety of downstream molecules, and by inhibiting these kinases, PP2 can inhibit the activation of proteins such as 2300002D11Rik that may rely on Src kinase activity for their function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src family kinases. By inhibiting these kinases, Dasatinib can inhibit the function of downstream targets including 2300002D11Rik, which may rely on Src kinase-mediated signaling for activation. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor. By inhibiting EGFR, Erlotinib disrupts the EGFR signaling pathway, which could be crucial for the function of 2300002D11Rik if it is involved in this pathway, leading to the inhibition of the protein. | ||||||